Open Label Study To Evaluate The Long-Term Safety Profiles Of Caduet In Japanese Patients

Inclusion Criteria: * Subject with both hypertension and hypercholesterolemia must meet the following (1), and the following (2) or (3): * (1) Subjects who take Amlodipine 2.5mg/day or 5mg/day at least 28 days before Week -2, and Subjects with well controlled BP value (BP value \< 140/90mmHg at Week 0) * (2) Subjects who take Atorvastatine 5mg/day or 10mg/day at least 28days before Week -2 * (3) Statin-naïve patient, defined as receiving no statin therapy for more than 3 months during the previous 12 months, with LDL-C ≥ 160 mg/dL, LDL-C \< 250 mg/dL, and TG \< 400 mg/dL at Week -2 * Subject with both angina pectoris and hypercholesterolemia must meet the following (1), and the following (2) or (3): * (1) Subjects who take Amlodipine 2.5mg/day or 5mg/day at least 28 days before Week -2, and who meet the following criteria; Subjects with well controlled BP value (BP value \< 140/90mmHg at Week 0), and subjects with clinically stable of angina pectoris * (2) Subjects who take Atorvastatine 5mg/day or 10mg/day at least 28days before Week -2 * (3) Statin-naïve patient, defined as receiving no statin therapy for more than 3 months during the previous 12 months, with LDL-C ≥ 160 mg/dL, LDL-C \< 250 mg/dL, and TG \< 400 mg/dL at Week -2 Exclusion Criteria: * Subjects who need three or more multi-antihypertensive therapies to achieve the target BP level or uncontrolled status of hypertension at Week 0 (V1); the target BP level is defined as systolic blood pressure \< 140mmHg and diastolic blood pressure \< 90 mmHg. * Uncontrolled or uncontrollable status of hypercholesterolemia at Week -2; A LDL-C ≥ 160 mg/dL even though Atorvastatine 10 mg has administrated